Loading stock data…
JAZZ
$202.72-0.30 (-0.15%)
Market ClosedLast close May 1
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jazz Pharmaceuticals plc in the Healthcare sector is trading at $202.72. The stock is currently near its 52-week high of $207.48, remaining 29.6% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why JAZZ maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$202.72
Potential Upside
5%
Whystock Fair Value$212.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$226.12+11.5%
Range$188.00 – $275.00
Fundamentals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.37%
Volume
Today's trading volume
550,385
Recent News
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative
Jazz Pharmaceuticals recently announced that it and its partners will present three rapid oral and seven poster oncology data sets at the 2026 ASCO Annual Meeting in Chicago, including Phase 3 results for Ziihera (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma and Zepzelca (lurbinectedin) in extensive-stage small cell lung cancer. For investors, the breadth of late-stage and real-world evidence around zanidatamab and Zepzelca highlights how Jazz is trying to build depth...
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Jazz Pharmaceuticals (NASDAQ:JAZZ) and the best and worst performers in the pharmaceuticals industry.
Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 10 Best Fast Growth Stocks to Invest In Now. On April 19, 2026, Barclays analyst Etzer Darout raised the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $225 from $224 and maintained an Overweight rating on the shares as part of a Q1 preview across the small […]
3 Overrated Stocks with Warning Signs
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
What a time it’s been for Jazz Pharmaceuticals. In the past six months alone, the company’s stock price has increased by a massive 46%, reaching $200.71 per share. This performance may have investors wondering how to approach the situation.